Danaher (DHR) Peer Comparison
$230.25
$3.91
(1.73%)
As on 06-Nov-2026 16:02EST
Market cap
$159,114 Mln
Revenue (TTM)
$25,608 Mln
P/E Ratio
37.5
P/B Ratio
3.1
Div. Yield
0.7 %
Edit
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
159,114 | 250,817 | 196,572 | 159,964 | 127,562 |
Revenue ($ Mln) |
25,608 | 47,351 | 48,229 | 11,578 | 26,300 |
Net Profit ($ Mln) |
4,331.00 | 7,083.00 | 4,701.00 | 2,957.20 | 3,623.00 |
Net Margin (%) |
16.91 | 14.96 | 9.75 | 25.54 | 13.78 |
RoE (%) |
8.13 | 13.24 | 9.12 | 17.58 | 15.60 |
Price to Earnings |
37.47 | 35.70 | 42.39 | 54.75 | 35.68 |
Price-To-Book |
3.08 | 4.78 | 3.91 | 10.35 | 5.51 |
Income Statement ($ Mln)
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
25,608.00 | 47,351.00 | 48,229.00 | 11,578.00 | 26,300.00 |
|
Cost of Revenue
|
10,603.00 | 27,729.00 | 20,681.00 | 3,798.50 | 9,067.00 |
|
Gross Profit
|
14,970.00 | 18,239.00 | 24,607.00 | 6,642.30 | 16,065.00 |
|
Operating Expenses
|
9,787.00 | 11,106.00 | 20,197.00 | 4,495.40 | 11,643.00 |
|
Operating Profit (EBIT)
|
5,218.00 | 8,515.00 | 7,351.00 | 3,284.10 | 5,590.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
4,818.00 | 7,869.00 | 6,562.00 | 3,619.00 | 5,116.00 |
|
Provision for Tax
|
487.00 | 742.00 | 1,861.00 | 645.90 | 1,493.00 |
|
Profit after Tax (Net Income)
|
4,331.00 | 7,083.00 | 4,701.00 | 2,957.20 | 3,623.00 |
|
Minority Interest
|
0.00 | -22.00 | 0.00 | -15.90 | 0.00 |
|
Consolidated Profit
|
1,197.00 | 1,964.00 | 1,776.00 | 0.00 | 849.00 |
Liabilities ($ Mln)
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
53,621.00 | 54,762.00 | 51,027.00 | 15,986.20 | 23,457.00 |
|
Minority Interest
|
0.00 | -22.00 | 0.00 | -15.90 | 0.00 |
|
Non-Current Liabilities
|
30,610.00 | 45,295.00 | 40,472.00 | 698.30 | 17,290.00 |
|
Current Liabilities
|
9,050.00 | 14,170.00 | 16,152.00 | 2,533.00 | 6,500.00 |
|
Total Liabilities
|
83,464.00 | 110,343.00 | 86,713.00 | 20,631.20 | 47,844.00 |
Assets ($ Mln)
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
78,494.00 | 88,618.00 | 84,751.00 | 10,920.80 | 33,064.00 |
|
Current Assets
|
14,787.00 | 25,615.00 | 23,496.00 | 8,428.30 | 14,183.00 |
|
Total Assets
|
83,464.00 | 110,343.00 | 86,713.00 | 20,631.20 | 47,844.00 |
|
Total Debt*
|
26,482.00 | 41,370.00 | 31,159.00 | 0.00 | 15,433.00 |
|
Net Current Assets
|
5,737.00 | 11,445.00 | 7,344.00 | 5,895.30 | 7,683.00 |
Cashflow ($ Mln)
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
6,416.00 | 7,818.00 | 9,566.00 | 3,030.50 | 5,044.00 |
|
Cash Flow from Investing Activities
|
-1,196.00 | -4,047.00 | -2,422.00 | 665.80 | -4,866.00 |
|
Cash from Financing Activities
|
-2,961.00 | 1,801.00 | -6,309.00 | -2,364.10 | 113.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
5.25 | 7.69 | 10.03 | 16.46 | 8.83 |
|
ROE (%)
|
8.13 | 13.24 | 9.12 | 17.58 | 15.60 |
|
ROA (%)
|
4.59 | 5.75 | 4.21 | 13.74 | 6.70 |
|
EBIT Margin (%)
|
20.22 | 18.92 | 15.09 | 33.80 | 20.59 |
|
Net Margin (%)
|
16.91 | 14.96 | 9.75 | 25.54 | 13.78 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
5.52 | 8.27 | 10.00 | 20.45 | 7.87 |
|
EBIT Growth (%)
|
16.46 | 4.98 | -15.99 | 23.61 | 48.61 |
|
Net Profit Growth (%)
|
23.64 | 7.81 | -66.37 | 7.66 | 23.11 |
|
EPS Growth (%)
|
26.16 | 9.68 | -66.31 | 9.30 | 23.26 |
|
Book Value Growth (%)
|
6.02 | 9.36 | 0.78 | -2.83 | 8.23 |
Valuation Ratios
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
45.04 | 32.43 | 33.55 | 71.47 | 41.85 |
|
Price / Book Value
|
3.08 | 4.78 | 3.91 | 10.35 | 5.51 |
|
Dividend Yield (%)
|
0.65 | 0.26 | 2.18 | 0.00 | 1.04 |
|
EV/EBITDA
|
24.40 | 24.92 | 20.88 | 36.83 | 21.12 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.45 | 0.71 | 0.58 | 0.00 | 0.60 |
|
Short term debt to equity ratio
|
0.04 | 0.04 | 0.03 | 0.00 | 0.04 |
|
Current Ratio
|
1.63 | 1.81 | 1.45 | 3.33 | 2.18 |
|
Quick Ratio
|
1.29 | 1.41 | 1.00 | 2.49 | 1.30 |
|
Interest Coverage
|
14.38 | 6.12 | 8.37 | -- | 7.29 |
Operating Efficiency Ratios
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
20.02 | 20.33 | 18.73 | 14.87 | 14.04 |
|
Asset Turnover
|
0.27 | 0.38 | 0.43 | 0.54 | 0.49 |
|
Receivable days
|
61.72 | 82.76 | 61.20 | 54.16 | 58.36 |
|
Inventory Days
|
91.69 | 72.19 | 117.44 | 177.54 | 203.47 |
|
Payable days
|
68.44 | 46.50 | 78.11 | 23.93 | 70.18 |
|
Cash Conversion Cycle
|
84.97 | 108.45 | 100.53 | 207.78 | 191.65 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
